Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

about

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Item

http://www.wikidata.org/entity/Q55352057

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@en

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@nl

type

Item

label

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@en

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@nl

prefLabel

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@en

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@nl

P1476

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

@en

P2093

Ada Girnita

http://www.w3.org/2001/XMLSchema#string

Hildur Helgadottir

http://www.w3.org/2001/XMLSchema#string

Iara Rocha Trocoli Drakensjö

http://www.w3.org/2001/XMLSchema#string

P2860

{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase

Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor

BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization

Germline mutations in BAP1 predispose to melanocytic tumors

A landscape of driver mutations in melanoma

Patient-derived tumour xenografts as models for oncology drug development

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

One mouse, one patient paradigm: New avatars of personalized cancer therapy

P304

202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00202

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29946532

http://www.w3.org/2001/XMLSchema#string

P932

6006716

http://www.w3.org/2001/XMLSchema#string